The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/22774396
Conclusion of this study
The combined administration of MI and DCI in physiological plasma ratio (40:1) should be considered as the first line approach in PCOS overweight patients, being able to reduce the metabolic and clinical alteration of PCOS and, therefore, reduce the risk of metabolic syndrome.
Supplements analyzed in this study
Health conditions analyzed in this study
Functions related to this study
Body systems related to this study